eCFR Reference Browser

---

title: "21 CFR §316.4"

source: "https://www.ecfr.gov/current/title-21/section-316.4"

title_number: "21"

volume_number: "5"

chapter_number: "Unknown"

subchapter_code: "D"

subchapter_subject: "DRUGS FOR HUMAN USE"

part_code: "316"

part_subject: "ORPHAN DRUGS"

subpart_code: "A"

subpart_subject: "General Provisions"

section_number: "316.4"

section_subject: "Address for submissions."

cfr_reference: "21 CFR 316.4"

title_name: "Title 21"

title_subject: "Food and Drugs"

parts_covered: "Parts 300 to 499"

revised_date: "Revised as of April 1, 2019"

publication_date: "As of April 1, 2019"

contains_description: "Containing a codification of documents of general applicability and future effect"

publication_info: "Published by the Office of the Federal Register National Archives and Records Administration as a Special Edition of the Federal Register"

---

All correspondence and requests for FDA action under the provisions of this rule should be addressed as follows: Office of Orphan Products Development, Food and Drug Administration, Bldg. 32, Rm. 5271, 10903 New Hampshire Ave., Silver Spring, MD 20993.

§316.4 - Address for submissions.